Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multif...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Mariana Vieira Morau, Cecilia Souto Seguin, Mauricio Wesley Perroud Junior, Carolina Dagli-Hernandez, Eder de Carvalho Pincinato, Patricia Moriel
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-08-01
Serie:	Pharmaceuticals
Soggetti:	gefitinib adverse drug reaction skin rash pharmacogenetics <i>ABCB1</i> cytochrome P450 enzyme system
Accesso online:	https://www.mdpi.com/1424-8247/17/8/1040
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!